Athenex, inc. reaches agreement with lenders to pursue expedited sales process

To best facilitate, company voluntarily files chapter 11 proceedings company has sufficient resources to support athenex pharma solutions operations  and fulfill apd customer orders during process buffalo, n.y., may 14, 2023 (globe newswire) -- athenex, inc., (nasdaq: atnx) (“athenex” or the “company”), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoing strategic review, it has reached agreement with its lenders to move forward with an expedited sales process of the company's assets across its primary businesses: athenex pharmaceutical division (“apd”), orascovery, and cell therapy.
ATNX Ratings Summary
ATNX Quant Ranking